文献速递肝病消化道肿瘤与早癌

墨西哥裔美国人肝细胞癌患者一级亲属的肝纤维化患病率及相关因素

Prevalence and factors associated with liver fibrosis among first-degree relatives of Mexican Americans with hepatocellular carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2023-01-10

本研究基于西班牙裔肝癌队列的前瞻性数据,横断面分析70例墨西哥裔美国人肝细胞癌先证者及其112名一级亲属,采用瞬时弹性成像评估肝纤维化。一级亲属中显著纤维化患病率为17%,明确肝脂肪变为42%;糖尿病和天冬氨酸氨基转移酶≥30 U/L是显著纤维化的预测因素。作者认为该人群可能受益于肝病筛查。

要点

  • 墨西哥裔美国人肝细胞癌患者一级亲属中显著纤维化患病率为17%,明确肝脂肪变为42%。
  • 40岁及以上一级亲属显著纤维化患病率为20%。
  • 糖尿病(OR 3.2)和天冬氨酸氨基转移酶≥30 U/L(OR 4.0)是显著纤维化的预测因素。

核心结论

  • 在特征明确的家系队列中,墨西哥裔美国人肝细胞癌患者的一级亲属中显著纤维化和明确肝脂肪变患病率较高,尤其是糖尿病患者,提示该人群可能受益于肝病筛查。

研究设计与样本

  • 西班牙裔肝癌队列研究的前瞻性队列横断面分析,纳入70例墨西哥裔美国人肝细胞癌先证者及112名一级亲属。

主要发现

  • 先证者70例,女性占47%,平均年龄62岁(±13岁)。
  • 一级亲属112名,平均年龄43岁(±14岁),19名(17%)有显著纤维化,47名(42%)有明确肝脂肪变。
  • 40岁及以上一级亲属中显著纤维化患病率为20%。
  • 回归分析显示糖尿病(OR 3.2,95% CI:1.1-9.2,p=0.03)和天冬氨酸氨基转移酶≥30 U/L(OR 4.0,95% CI:1.4-11.7,p=0.01)是一级亲属显著纤维化的预测因素。

关键数值与推荐

  • 显著肝纤维化定义为瞬时弹性成像肝硬度测量值≥7.0 kPa。
  • 明确肝脂肪变定义为受控衰减参数≥288 dB/m。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Whether hepatocellular carcinoma (HCC) increases the familial risk for hepatic fibrosis has not been thoroughly explored, particularly in Mexican Americans who are disproportionately affected by obesity and metabolic syndrome. We evaluated the risk of significant hepatic fibrosis in first-degree relatives of Mexican American adults with HCC. METHODS: We performed a cross-sectional analysis of a prospective cohort of Mexican American probands with HCC and first-degree relatives enrolled in the Hispanic Liver Cancer Cohort study. We evaluated the prevalence of hepatic fibrosis in first-degree relatives, defined by liver stiffness measurement (LSM) >= 7.0 kPa with transient elastography (TE). Secondary outcomes included the prevalence of definite hepatic steatosis, defined by controlled attenuation parameter >=288 dB/m. RESULTS: We identified 70 probands diagnosed with HCC; 47% were female and the mean age was 62 years (±13 years). Among 112 first-degree relatives with a mean age of 43 years (±14 years), 19 (17%) had significant fibrosis and 47 (42%) had definite hepatic steatosis, respectively. The prevalence of significant fibrosis was 20% in first-degree relatives 40 years of age or older. Regression analysis revealed that diabetes (OR 3.2, 95% CI: 1.1-9.2, p = 0.03) and aspartate aminotransferase >=30 units/L (OR 4.0, 95% CI: 1.4-11.7, p = 0.01) were predictors of significant fibrosis in first-degree relatives. CONCLUSIONS: Using a well-phenotyped familial cohort, we found that the prevalence of significant fibrosis and definite hepatic steatosis are high in first-degree relatives of Mexican Americans with HCC, particularly those with diabetes, suggesting that this population may benefit from screening for liver disease.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sharpton S, Shan K, Bettencourt R, et al. Prevalence and factors associated with liver fibrosis among first-degree relatives of Mexican Americans with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023. PMID: 36628455. doi:10.1111/apt.17384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。